Shire inks $516MM deal for Germany's Jerini; Bayer buys Maxygen hemophilia unit

> Britain's Shire is set to acquire Berlin-based biotech Jerini a $516 million deal, with the specific intention of adding Jerini's Firazyr orphan drug product for hereditary angioedema to its portfolio. Report

> AstraZeneca's Seroquel patent victory not only boosted AstraZeneca's stock yesterday but prompted analysts to issue more favorable opinions for pharma as a whole. Report

> Nine out of 10 U.K. adults believe allowing top-up payments--for expensive drugs not covered by the National Health Service--would mark the end of the NHS model of providing equal access to all, a Financial Times survey showed. Report

> Bayer's health care unit is buying Maxygen's hemophilia unit for $90 million upfront and potential future fees of up to $30 million in a move to expand its specialty pharmaceutical business. Report

> India's Glenmark Pharmaceuticals said its Czech subsidiary Medicamenta has inked agreements with generics maker Actavis to acquire seven pharmaceutical brands in Poland; the deal puts Glenmark in the Polish market for the first time. Report

> The Generic Pharmaceutical Association spent $434,495 lobbying in the first quarter on issues affecting the drug industry, according to a recent disclosure report. Report

> Shrinking pharmaceuticals production pushed Singapore's industrial output growth into negative territory for the second month in a row. Report

> Pharmaceutical sales in Spain rose 8.6 percent in 2007 to $20.8 billion, with treatments for the nervous system, cardiovascular, digestive system and respiratory system the top sellers, according to Farmaindustria. Report

> India's FDC received FDA approval for its antibiotic eye drug Ciprofloxacin Ophthalmic Solution. Report

> Titan Pharmaceuticals announced this morning that its Parkinson's drug Spheramine failed to hit primary and secondary endpoints in a Phase IIb trial for moderate to advanced Parkinson's disease. Report

> Celera has ended its run as a biotech drug developer, completing its switch to molecular diagnostic testing company and moving its HQ from Rockville, MD to Alameda California. Report

> The new CEO at Roche is sending out some strong signals that the pharma giant's development process will include more new therapies for primary care. Report

> Maxygen has inked a deal to sell its hemophilia drug development program to Bayer for $90 million upfront and up to $30 million in milestone payments. Maxygen report

And Finally... The American Academy of Pediatrics say that more and more parents are resisting the vaccinations that are recommended for their children, and they're mounting a promotional campaign in an attempt to reverse the tide. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.